IMRX
Price
$3.79Alerts
Change
-$0.06 (-1.56%)
Updated
Nov 11 closing price
Capitalization
238.09M
120 days until earnings call
Intraday BUY SELL Signals
JSPR
Price
$14.76Alerts
Change
+$0.01 (+0.07%)
Updated
Nov 11 closing price
Capitalization
561.01M
118 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IMRX vs JSPR

IMRX vs JSPR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
IMRX vs. JSPR commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMRX is a Buy and JSPR is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for IMRX with price predictions
Nov 10, 2026

IMRX in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 05, 2026

IMRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 37 cases where IMRX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IMRX's RSI Oscillator exited the oversold zone, 23 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 60 cases where IMRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on IMRX as a result. In 80 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.

The Moving Average Convergence Divergence (MACD) for IMRX just turned positive on October 20, 2026. Looking at past instances where IMRX's MACD turned positive, the stock continued to rise in 35 of 40 cases over the following month. The odds of a continued upward trend are 88%.

Following a +7.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMRX advanced for three days, in 220 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for IMRX entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. IMRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.248) is normal, around the industry mean (3.498). P/E Ratio (-3.957) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for JSPR with price predictions
Nov 10, 2026

Momentum Indicator for JSPR turns negative, indicating new downward trend

JSPR saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned negative. In 84 of the 92 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JSPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

JSPR broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for JSPR entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for JSPR just turned positive on October 23, 2026. Looking at past instances where JSPR's MACD turned positive, the stock continued to rise in 32 of 37 cases over the following month. The odds of a continued upward trend are 86%.

Following a +6.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where JSPR advanced for three days, in 203 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. JSPR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: JSPR's P/B Ratio (397.034) is very high in comparison to the industry average of (3.498). P/E Ratio (-18.129) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JSPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
JSPR: Fundamental Ratings
JSPR
OUTLOOK RATING
1..100
74
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
81
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
47

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
IMRXJSPR
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 8 days ago
88%
Bullish Trend 15 days ago
84%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (IMRX: $3.85 vs. JSPR: $14.75)
Brand notoriety: IMRX and JSPR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMRX: 86% vs. JSPR: 248%
Market capitalization -- IMRX: $238.09M vs. JSPR: $561.01M
IMRX [@Biotechnology] is valued at $238.09M. JSPR’s [@Biotechnology] market capitalization is $561.01M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMRX’s FA Score shows that 1 FA rating(s) are green while JSPR’s FA Score has 0 green FA rating(s).

  • IMRX’s FA Score: 1 green, 4 red.
  • JSPR’s FA Score: 0 green, 5 red.
According to our system of comparison, IMRX is a better buy in the long-term than JSPR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMRX’s TA Score shows that 6 TA indicator(s) are bullish while JSPR’s TA Score has 2 bullish TA indicator(s).

  • IMRX’s TA Score: 6 bullish, 2 bearish.
  • JSPR’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, IMRX is a better buy in the short-term than JSPR.

Price Growth

IMRX (@Biotechnology) experienced а +4.62% price change this week, while JSPR (@Biotechnology) price change was +2.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

IMRX is expected to report earnings on Mar 11, 2027.

JSPR is expected to report earnings on Mar 09, 2027.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

IMRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMRX has been loosely correlated with ACRV. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if IMRX jumps, then ACRV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMRX
1D Price
Change %
IMRX100%
+5.48%
ACRV - IMRX
52%
Loosely correlated
-0.63%
CRMD - IMRX
50%
Loosely correlated
-1.83%
JSPR - IMRX
40%
Loosely correlated
-9.90%
LXEO - IMRX
40%
Loosely correlated
-2.55%
GHRS - IMRX
39%
Loosely correlated
+1.56%
More

JSPR and

Correlation & Price change

A.I.dvisor indicates that over the last year, JSPR has been loosely correlated with AUPH. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if JSPR jumps, then AUPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JSPR
1D Price
Change %
JSPR100%
-9.90%
AUPH - JSPR
44%
Loosely correlated
-1.93%
IMRX - JSPR
40%
Loosely correlated
+5.48%
FRMM - JSPR
38%
Loosely correlated
-2.08%
NXTC - JSPR
37%
Loosely correlated
-4.63%
BNTC - JSPR
35%
Loosely correlated
-5.98%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EWO41.210.11
+0.27%
iShares MSCI Austria ETF (EWO)
DFLV41.930.09
+0.22%
Dimensional US Large Cap Value ETF (DFLV)
ICLO25.590.01
+0.04%
Invesco AAA CLO Floating Rate Note ETF (ICLO)
MMSC26.40-0.19
-0.73%
First Trust Multi-Manager Small Cap Opportunities ETF (MMSC)
BRAZ27.43-0.49
-1.74%
Global X Brazil Active ETF (BRAZ)